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The leishmaniases are multifactorial zoonotic diseases requiring a multidisciplinary One 27 
Health approach for diagnosis and control. For leishmaniasis diagnosis, here we describe 28 
production of a new recombinant protein based on a kinesin-related gene of Leishmania 29 
braziliensis (Lbk39), which shows 59% amino acid identity to the L. infantum 30 
homologue. The Lbk39 gene was synthesised, inserted into the pLEXSY-sat2 vector and 31 
transfected into L. tarentolae cells by electroporation. Culturing was carried out, and the 32 
secreted recombinant protein with a C-terminal histidine tag purified using nickel affinity 33 
chromatography on the culture supernatant, yielding a final product at 0.4 mg/mL. An 34 
indirect enzyme linked immunosorbent assay (ELISA) was standardised using sera from 35 
74 Brazilian patients with cutaneous leishmaniasis and 11 with visceral leishmaniasis. 36 
Optimal ELISA conditions were established for the Lbk39 antigen in comparison with a 37 
crude extract from L. braziliensis. The sensitivity, specificity analysis and receiver 38 
operating characteristic (ROC) curve were determined with a significance level of 5%. 39 
The ROC curve showed a good accuracy with an area under curve (AUC) = 0.967, p < 40 
0.001 (0.941-0.993) for CL patients and an AUC = 100 (100-100) for VL patients. The 41 
values of sensitivity and specificity were 88 and 98% for CL and 100 and 100% for VL, 42 
respectively. The study showed good production and expression of the target protein and 43 
has generated a potential new antigen for the diagnosis of leishmaniasis.  44 
 45 
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1. Introduction  49 
The leishmaniases are a group of largely zoonotic, vector-borne diseases transmitted by 50 
sand flies and caused by heteroxenous parasites of the genus Leishmania Ross, 1903. The 51 
complexity of their epidemiology means they require a One Health approach for their 52 
diagnosis and control, and they present a significant ongoing global public health 53 
challenge (Alvar et al., 2012; Vilas et al., 2014). Three varieties of epidemiological cycles 54 
are known: a sylvatic cycle in which human infection is accidental and transmission 55 
occurs in wild foci; a peridomestic cycle in which the reservoirs of infection are domestic 56 
animals and transmission to humans occurs around or within human dwellings; and an 57 
anthroponotic cycle in which transmission is human to human via anthropophilic sand 58 
flies (Burza et al., 2018). Depending on the parasite species and disease focus various 59 
combinations of these cycles may co-exist. Another layer of complexity is provided by 60 
the environmental factors that influence mammalian reservoir and sand fly vector 61 
distributions. For example, the emergence of new foci or re-emergence of leishmaniases 62 
has occurred due to invasion of the sand flies into urban areas (Thomaz-Soccol et al. 63 
2018). 64 
Upon infection these parasites interact with the host immune system in a variety 65 
of ways to enhance their survival (Kaye and Scott, 2011). A common feature of infection 66 
is that the ability of the host to control the parasite depends on the production of cell-67 
mediated immune responses, which in turn are able to activate macrophages to eliminate 68 
the intracellular parasites (Taslimi et al. 2018). Although the resolution of the infection is 69 
largely mediated by Th1 cells secreting IFN-γ in response to an increase of IL-12, there 70 
is also development of a Th2 cell response. The resulting increase of IL-4 can result in 71 
progression of lesions and lead to systemic disease, but in addition, some Leishmania 72 
antigens can drive the differentiation of T-cells that can activate B-lymphocytes to 73 
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produce immunoglobulins. It is also known that antibodies are produced through 74 
neutrophil stimulation at the very beginning of the infection. Although various studies 75 
suggest that such antibodies play no role in host protection, they can be useful in diagnosis 76 
for determining the presence of the parasite (Al-Qadhi et al., 2015; Martins et al., 2016). 77 
The correct diagnosis of the leishmaniases is performed through a combination of 78 
clinical, epidemiological and laboratory findings (Szargiki et al., 2009). A range of 79 
diagnostic tools is available, but none of them are perfect and new more reliable 80 
diagnostic tests must still be developed, which should be easy to handle, cheap to produce, 81 
and perform with high sensitivity and specificity (Maia et al., 2012). Some purified 82 
recombinant antigens of various Leishmania species have been produced and used in 83 
serological assays, such as the rK39 antigen for the serodiagnosis of visceral 84 
leishmaniasis (VL) (Badaro et al., 1996; De Vries et al., 2015). The rK39 antigen is a 85 
recombinant protein derived from Leishmania infantum that contains 6.5 tandem copies 86 
of a B-cell antigenic epitope composed of 39 amino acids. This antigen is related to a 87 
kinesin motor protein, which is well conserved between L. infantum and L. donovani, and 88 
the corresponding gene reveals a single open-reading frame that encodes a total of 298 89 
amino acids with a predicted molecular mass of 32.7 kDa (Burns et al., 1993). The 90 
Leishmania motor protein is involved in various intracellular processes and is present in 91 
the amastigote forms of many species.  92 
Production of an antigenic protein of Leishmania, by heterologous expression of 93 
its specific epitopes in a prokaryotic system such as Escherichia coli, is a relatively 94 
straightforward technique that is both inexpensive for culturing and quick for processing 95 
the target recombinant protein. However, such systems lack eukaryotic post-translational 96 
activity, which is a significant disadvantage in producing many eukaryotic proteins. 97 
Further, high concentrations of the unfolded protein can occur, leading to a decline in 98 
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effective yield, and culturing at a temperature optimal for E. coli can also reduce yields 99 
of recombinant protein and increase protein degradation (Khow and Suntrarachun, 2012). 100 
The protozoan Leishmania tarentolae, which is not pathogenic to mammals, has been 101 
explored as a general eukaryotic host to develop a platform that allows complex 102 
eukaryotic protein expression at high levels, and which also has the ability to produce 103 
proteins with appropriate post-translational processing (Basile and Peticca, 2009). 104 
Moreover, the host is easy to manipulate and can be cultivated on a cheap medium with 105 
a 6 to 8 h doubling time. The maintenance of a transfected culture of L. tarentolae is 106 
performed under specific antibiotic selection and maintains the same level of protein 107 
expression after several months of culturing (Breitling et al., 2002; Kushnir et al., 2011; 108 
Klatt and Konthur, 2012). Finally, specifically with respect to this study, when the desired 109 
recombinant antigen itself is derived from a species of Leishmania use of this system 110 
maximises the probability of successful expression. 111 
Based on what has been described above, the aim of this study was to explore the 112 
use of L. tarentolae as a host for the expression and secretion of a L. braziliensis kinesin-113 
related recombinant protein, which was identified based on the reference kinesin-related 114 
rK39 gene of L. infantum. The diagnostic efficiency of this new antigen was evaluated by 115 
developing an indirect ELISA for leishmaniasis detection. Until now, no studies have 116 
reported on the levels of antibodies against L. braziliensis kinesin in cutaneous 117 
leishmaniasis (CL) patients. 118 
 119 
2. Materials and Methods 120 
 121 
2.1 Serum sample collection 122 
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The patients enrolled in the study were divided into four groups, according to clinical 123 
classification (Table 1). In Group 0, 50 healthy individuals from a non-endemic area and 124 
medically examined to eliminate any previous CL infection, were used to determine the 125 
cut off for the ELISA test and the specificity. Patients with L. braziliensis, diagnosed with 126 
infection by parasite isolation and clinical examination, were classified in Group 1 127 
(n=74). Patients with L. infantum diagnosed by serology and PCR were classified in the 128 
Group 2 (n=11). Patients with a positive leishmaniasis diagnosis were treated, by local 129 
service staff, in accordance with the guidelines of the Brazilian Ministry of Health, as 130 
described in the Manual of surveillance and control of American Integumentary 131 
Leishmaniasis (2010). Patients with Chagas disease (n=13), confirmed by serology, were 132 
also studied to assess the possibility of cross-reactivity. Patient serum samples were 133 
stored frozen (-20°C) before use. 134 
This study was conducted in accordance with the International Ethical Guidelines for 135 
Biomedical Research in Human Beings. In addition, ethical approval was obtained from 136 
the Universidade Federal do Paraná Ethical Committee under number 684.244, and in 137 
accordance with the law of the Southern Common Market Treaty (Mercosur), Resolution 138 
No. 129/96.  139 
 140 
2.2 Lbk39 plasmid construction, cloning, and propagation in Escherichia coli 141 
A homology search was performed by means of BLAST similarity (Altschul et al., 1997) 142 
in the TritrypDB database website. Sequences derived from a kinesin-related gene of L. 143 
braziliensis, henceforth called Lbk39, and comprised of 828 nucleotides (nt) were used 144 
for initial plasmid construction (Suppl. Fig. 1A). These were identified by homology with 145 
the kinesin-related gene of L. infantum - Genebank: L07879, described by Burns et al. 146 
(1993), and containing 39 amino acid repeats. Lbk39 also contains a related 39 amino 147 
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acid sequence (Suppl. Fig. 1B) and is also predicted to comprise immunologically 148 
dominant B-cell epitopes (BepiPred; http://www.cbs.dtu.dk/services/BepiPred/ ).   149 
 For expression of the target recombinant protein, the synthetic gene Lbk39 was 150 
assembled from synthetic oligonucleotides by Invitrogen (Germany), and the fragment 151 
was inserted into the pLEXSY-sat2 recombinant vector, developed by Jena Bioscience 152 
(Germany), and cloned with a 6×His-tag into the corresponding site of the above-153 
mentioned recombinant vector. The expression vector was designed for integration into 154 
the chromosomal 18SrRNA (ssu) locus of the parasite (Breitling et al., 2002), allowing 155 
for the true expression of the eukaryotic protein; also, for this specific study, the target 156 
protein was selected to be secreted into the culture medium.   157 
 Following the construction of the Lbk39 plasmid, the One Shot™TOP10 158 
Chemically Competent Escherichia coli strain (Invitrogen) was chosen for the plasmid 159 
cloning and propagation, and the procedure for culturing was followed according to the 160 
manufacturer’s instructions, except for the incubation temperature, which was 30 °C for 161 
plasmid stability reasons. After that, the plasmid was purified from the E. coli strain using 162 
the Geneflow Q-Spin Plasmid DNA Purification Kit and was sent for sequencing. The 163 
forward P1442 (5’-CCGACTGCAACAAGGTGTAG-3’) and reverse A264 (5’-164 
CATCTATAGAGAAGTACACGTAAAAG-3’) sequencing primers, included in the 165 
LEXSY kit, were used to confirm the plasmid identity and sequence. 166 
 167 
2.3 Lkb39 plasmid transfection into LEXSY culture and Lbk39 LEXSY culturing 168 
The propagated and purified Lbk39 plasmid from the E. coli strain was linearised through 169 
digestion with the SwaI (SmiI) enzyme, from Streptococcus milleri S - 10U/µL (Thermo 170 
Fischer Scientific), to prepare for plasmid transfection into the LEXSY host L. tarentolae, 171 
according to the manufacturer’s protocol. To confirm the correct procedure for 172 
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linearization and to isolate the fragment corresponding to the plasmid, 1% agarose gel-173 
isolation of the expression cassette with an Agarose Gel Extraction Kit (Jena Bioscience) 174 
was performed according to the manufacturer’s instruction.  The LEXSY strain was 175 
previously prepared for transfection according to the LEXSYcon2 Expression Kit manual 176 
(for detail see https://www.jenabioscience.com /images/ ae3a4f50f1/EGE-1310.pdf). 177 
When ready for transfection through electroporation, the cultured cells were handled 178 
according to the same manual mentioned above. Other aliquots of LEXSY cells were 179 
electroporated without DNA under the same conditions as a negative control. Then the 180 
electroporated cells were transferred to tissue culture flasks containing 10-mL Brain 181 
Heart Infusion (BHI) medium supplemented with porcine hemin (Jena Bisocience) and 182 
penicillin and streptomycin (Pen-Strep, Jena Bioscience) at 26 °C in the dark under 183 
aerated conditions. As soon as the cultures became slightly turbid (24 h after 184 
electroporation), the specific Streptothricin-class of aminoglycoside antibiotic 185 
Nourseothricin (LEXSY NTC, Jena Bioscience) for the pLEXSY-sat2 vector was added, 186 
and the culture maintained under the same conditions by subpassage every four days.  187 
The genomic integration of the Lbk39 plasmid into the chromosomal 18SrRNA 188 
(ssu) locus of L. tarentolae strain was confirmed by PCR. Genomic DNA was extracted 189 
from 2 mL of a dense Lbk39 LEXSY culture by means of the DNeasy Blood and Tissue 190 
Quick-start kit (Qiagen) according to the manufacturer’s recommendation. After that, 200 191 
ng of genomic DNA was added to two 0.2-mL microtubes (100 ng in each), containing 192 
the mixed solution of ultra-pure RNAse-free water, 5xHotStar HiFidelity PCR Buffer 193 
(including dNTPs), HotStar HiFidelity DNA Polymerase from HotStar HiFidelity 194 
Polymerase Kit (Qiagen) and into the first tube the specific primers (Jena Bioscience) for 195 
the genomic integration diagnostic: the F3001 forward primer (5’-196 
GATCTGGTTGATTCTGCCAGTAG-3’), responsible for the integration of all ssu 197 
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expression vectors; and the A1715 reverse primer (5’-198 
TATTCGTTGTCAGATGGCGCAC-3’), responsible for the integration of all “AP” 199 
expression vectors with 5'UTR aprt. The second tube was prepared identically except for 200 
the primers (Jena Bioscience): the F2999 forward primer (5’-201 
CCTAGTATGAAGATTTCGGTGATC-3’), responsible for the integration diagnostics 202 
of all sat expression vectors; and the F3002 reverse primer (5’-203 
CTGCAGGTTCACCTACAGCTAC-3’), responsible for the integration diagnostics of 204 
all ssu integration vectors. The PCR conditions for the F3001/A1715 pair of primers were 205 
as follows: 1 cycle at  95 °C for 5 min for the initial denaturation, followed by 35 cycles 206 
of 95 °C for 30 s, 60 °C for 30 s and 72 °C for 1 min, and 1 cycle at 72 °C for 10 min for 207 
final extension; whereas the PCR conditions for the F2999/F3002 pair of primers were: 1 208 
cycle of  95 °C for 5 min, followed by 35 cycles of 95 °C for 30 s, 53°C for 30 s and 72 209 
°C for 1 min, and 1 cycle at 72 °C for 10 min.  210 
Lbk39 recombinant protein purification was carried out using a HisTrap HP 1-mL 211 
column (GE HealthCare) by loading the culture media onto the column according to the 212 
manufacturer’s instructions. Afterwards, salts and imidazole were removed by dialysis in 213 
a PBS buffer at 4 °C, twice for 2 h and once overnight. Then, lyophilisation was 214 
performed to concentrate the purified recombinant protein. To analyse whether the 215 
purification process had been successful, the purified and dialysed recombinant protein 216 
was concentrated with trichloroacetic acid (TCA), as indicated in the LEXSYcon2 217 
Expression kit manual, loaded on a 15% SDS-polyacrylamide gel electrophoresis (SDS-218 
PAGE), and stained with silver nitrate.  The protein determination was performed using 219 
the Micro BCA™ Protein Assay Kit (Thermo Fischer Scientific) following the 220 




2.4 Enzyme-linked immunosorbent assay (ELISA) 223 
To determine whether levels of anti-Leishmania antibodies in human serum from 224 
uninfected individuals and those infected with CL and other diseases can be detected 225 
using Lbk39 epitopes, optimal ELISA conditions were established (De Souza et al., 226 
2018). A range of serum dilutions (1:100, 1:200, 1:400 and 1:800), antibody-conjugate 227 
dilutions (1:5,000, 1:10,000 and 1:20,000) and antigen dilutions (0.1 µg, 0.5 µg and 0.85 228 
µg/100 µL/well) were tested in various combinations. 229 
High-binding polystyrene microtiter plates (96 well EIA/RIA 1x8 Stripwell Plate, 230 
Costar, USA) were coated overnight at 4 °C with 100 µL/well solution of antigen diluted 231 
in a carbonate–bicarbonate buffer (pH 9.6). On the following day, the plates were washed 232 
twice with 200 μL/well of a washing solution (0.9% w/v NaCl, 0.05% v/v Tween 20), 233 
and then the wells were blocked with 120 µL of a blocking solution (PBS + 0.1% w/v 234 
casein) for 1 h at 37 °C. Afterwards, they were washed twice again with 200 μL/well of 235 
the washing solution. Following the washing step, serum samples were diluted in an 236 
incubation solution (PBS + 0.25% w/v casein) and were added in their respective wells 237 
and incubated at 37 °C for 1 h. Then the plates were washed four times with 200 μL/well 238 
of the washing solution, and a polyclonal goat anti-human IgG HRP conjugate (2 mg/mL, 239 
SanBio Científica) was diluted and was added to each well for 1 h at 37 °C. Finally, the 240 
reaction was developed by adding 100 μL of a 10.5-mL citrate buffer (4.5% w/v Na2PO4, 241 
3.25% w/v citric acid, pH 5.0), with 2 mg of o-Phenylenediamine dihydrochloride (2 242 
mg/tablet, Sigma, USA) and 2 µL of 30% (w/w) H2O2 to each well at room temperature 243 
for 15 min, avoiding light, and then 20 µL of a solution 1:20 of H2SO4 was added to stop 244 
the reaction. Plates were read in a Powerwave HT reader (BioTek) at 492 nm, and values 245 
were expressed in absorbance. 246 
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Soluble proteins from the crude extract of L. braziliensis promastigotes (strain 247 
MHOM/BR/84/LTB300) were included in the study as a positive control. As additional 248 
controls, the pooled positive and negative serums were included in each plate when 249 
testing individual sera; each sample was measured in triplicate, and the whole assay 250 
described above was performed in duplicate.  251 
 252 
2.5 Statistical analysis 253 
The receiver operating characteristic (ROC) curve was derived based on the logistic 254 
regression model, considering the classification of the samples (presence or absence of 255 
the disease) as a dependent variable and each antigen as an independent variable. Logistic 256 
regression model, ROC curve and sensitivity and specificity analyses were performed 257 
using R software (R CORE TEAM, Version 3.4.4, 2018) with an auxiliary pROC system 258 
(Robin et al., 2011). We used analysis of variance (ANOVA) and Tukey’s test to compare 259 
the differences in absorbance between the groups. A significance level of p<0.05 was 260 
adopted. 261 
 262 
3. Results  263 
3.1 Lbk39 plasmid construction 264 
Gene synthesis using pLEXSY E.coli/L.tarentolae shuttle vectors was used to construct 265 
the Lbk39 plasmid, encoding L. braziliensis sequences homologous to the L. infantum 266 
rK39 antigen (Suppl. Fig. 1A). BLAST similarity sequence analysis of the cloned 267 
sequence confirmed it comprised a 843-bp product (828 plus 15 bp vector flanking 268 
sequences) homologous to the locus LBRM_14_1110 of L. braziliensis (strain 269 
MHOM/BR/75/M2904), and which exhibited 84% nucleotide sequence identity and 59% 270 
amino acid identity with the equivalent kinesin-related gene of L. infantum (Suppl. Fig. 271 
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1C). The predicted protein encoded a protein of 281 amino acids with a predicted 272 
molecular mass of 30 kDa, with six copies of 39 AA repeats. The cloned sequence was 273 
then inserted into the pLEXSY-sat2 vector for secretion and addition of a C-terminal 274 
6×His-tag (Suppl. Fig. 1B). The purification of the Lbk39 plasmid yielded 1.5 µg/µL of 275 
DNA, and plasmid identity was confirmed by sequencing the purified product, with 100% 276 
identity for both forward P1442 and reverse A264 sequencing primers. 277 
 278 
3.2 Lbk39 plasmid transfection into Leishmania tarentolae 279 
Linearization of the plasmid through digestion with the Swal (Smil) enzyme generated a 280 
2.9-kbp fragment related to the E. coli part and a larger fragment (approximately 5 kbp) 281 
related to the Lbk39 plasmid (Fig. 1A). The linearized plasmid was used to transfect L. 282 
tarentolae under antibiotic selection, and after approximately 10 days of Lbk39 LEXSY 283 
culturing, the cultures became turbid (107 cells/mL), and there was no noticeable growth 284 
of the parasites in the negative control flasks. On the 12th day of culturing, another 285 
passage was made, and 2 mL of that dense culture were withdrawn to perform the 286 
confirmation of Lbk39 genomic integration through PCR. For this objective, two pairs of 287 
primers were used: one of them amplifying from within the expression cassette and the 288 
other amplifying to a chromosomal ssu-flanking sequence that was not present on the 289 
plasmid. The PCR reactions resulted in two DNA fragments of different sizes, one for 290 
each pair of primers, as expected and indicated by the manufacturer: a 1.1 kbp fragment 291 
size for F3001/A1715 primers and a 2.3 kbp fragment size for F2999/F3002 (Fig. 1B). 292 
 293 
3.3 Purification of Lbk39 protein 294 
The Lbk39 protein was expressed as a 6xHis-tagged recombinant protein in the pLEXSY-295 
sat2 vector, inserted into the chromosomal 18SrRNA (ssu) locus of L. tarentolae and 296 
designed to be secreted into the culturing media with predicted molecular mass of 31.2 297 
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kDa (Suppl. Fig. 1B). The purification procedure and the protein expression were 298 
confirmed by SDS-PAGE, with the purified recombinant protein exhibiting a molecular 299 
mass of approximately 35 kDa (Fig. 2). The purified Lbk39 recombinant protein was 300 
obtained at a final concentration of 0.4 mg/mL. 301 
 302 
3.4 Enzyme-linked immunosorbent assay (ELISA) 303 
An indirect ELISA was developed and standardised using the recombinant protein as an 304 
antigen for detection of specific anti-Leishmania antibodies in the sera of leishmaniasis 305 
patients. The optimum combination of conditions were found to be as follows: antigen 306 
concentration of 0.1 µg/100 µL/well; serum samples diluted to 1:200 in incubation 307 
solution (PBS + 0.25% w/v casein); and polyclonal goat anti-human IgG HRP conjugate 308 
(2 mg/mL) diluted to 1:10,000.  309 
 The presence of anti-Leishmania antibodies was determined by comparing 310 
antibody levels in patients infected with CL and VL with healthy individuals living in the 311 
same endemic area, as well as individuals with Chagas disease, using the Lbk39 312 
recombinant protein as the antigen. The results obtained were compared using the same 313 
parameters and the same sample groups using as a positive control antigen a crude extract 314 
of L. braziliensis promastigotes. Comparing the two types of Leishmania antigen for 315 
patients known to have leishmaniasis, the Lbk39 antigen showed sensitivity of 88% for 316 
CL and of 100% for VL patients. The specificity was 98% and 100%, respectively (Table 317 
2 and Fig. 3). Based on the percentage positivity for all serum samples and sensitivity and 318 
specificity values, the Lbk39 antigen was able to detect antibodies from both CL and VL 319 
patients. The results obtained with the Lbk39 antigen were equivalent to or better than 320 
those using crude promastigote extract, except for a small reduction in specificity for CL 321 
patients (98% versus 100%). 322 
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The range of absorbance readings obtained in these assays are shown in Figure 4. 323 
Using the crude antigen, the range of readings obtained was high with the CL patients 324 
(Group 1), otherwise the readings were well grouped. However, the crude antigen also 325 
gave high readings with patients diagnosed with Chagas disease (Group 3). With the 326 
recombinant Lbk39 antigen the cross-reactivity with Chagas patient sera was much 327 
reduced, and the readings with the CL patient group were more tightly grouped. Even so 328 
the median value for the Chagas patients (Group 3) was still higher than that for CL 329 
patients. However, a wider range was found in the VL group using the LbK39 antigen. 330 
ANOVA indicated significant differences between the means of the various groups for 331 
both antigens. Pairwise comparisons using Tukey’s test showed these differences were 332 
significant (p < 0.05) in all cases except between Groups 1 and 2 (CL and VL patients) 333 
with L. braziliensis crude antigen, and between Groups 1 and 3 (CL and Chagas patients) 334 
with LbK39. In all cases the control patients (Group 0) were significantly different to all 335 
infection groups. 336 
 337 
4. Discussion 338 
Several recombinant proteins have been investigated for their anti-Leishmania 339 
antibody responses in patients in attempts to develop the most suitable antigens for 340 
diagnostic purposes, of which the best so far is the rK39 antigen for VL (Badaro et al. 341 
1996). However, although recombinant proteins have been extensively used for specific 342 
antibody detection, their use in diagnostic tests has revealed some problems. For example, 343 
they can be less immunoreactive than the corresponding purified antigen due to the 344 
absence of post-translational modifications, depending on the protein expression system. 345 
Further, their production in high quality and quantity is almost always laborious and they 346 
can be expensive to produce.  Here we explored the use of the pLEXSY/Leishmania 347 
tarentolae system for cloning, transfection and recombinant protein production for 348 
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leishmaniasis immunodiagnosis, in particular for the diagnosis of L. braziliensis 349 
infection.  350 
We designed a sequence based on L. braziliensis to generate a product that we 351 
named Lbk39, which exhibited 59% amino acid identity to the kinesin-related gene of L. 352 
infantum (rK39) that is already used in the serodiagnosis of VL. The Lbk39 sequence was 353 
synthesized, inserted into pLEXSY-sat2 recombinant vector and cloned with a 6×His-tag, 354 
then inserted into the chromosomal 18SrRNA (ssu) locus of L. tarentolae and selected to 355 
be secreted into the culturing media. Successful expression of a ~35kDa protein was 356 
achieved, correlating with the predicted molecular mass of the 289 amino acid 31.2 kDa 357 
recombinant protein (Suppl. Fig. 1B). Therefore, we can now add Lbk39 to the wide range 358 
of proteins that can be expressed in the L. tarentolae system (Kushnir et al., 2011). 359 
Recombinant protein production via large-scale fermentation of L. tarentolae is not 360 
expensive and allows yields of 0.1 to 5 mg/L to be achieved (Basile and Peticca, 2009; 361 
Mureev et al., 2009; Kovtun et al. 2011). As used in our study, improved expression is 362 
also obtained if the target gene is followed by the 3’-UTR (intergenic untranslated 363 
regions) from a highly expressed gene, because in trypanosomatids the regulation of 364 
protein expression generally occurs by a post-transcriptional process involving the UTRs 365 
as in present work (Niimi, 2012; Sugino and Niimi, 2012; Fernández and Veja, 2013). 366 
Expression and purification of the target antigen in the current study yielded recombinant 367 
Lbk39 antigen at 0.400 mg/mL.  368 
Lbk39 was evaluated for the serodiagnosis of CL due to L. braziliensis and 369 
showed 88% sensitivity and 98% specificity, compared to 98% sensitivity and 100% 370 
specificity in VL patients. Absorbance values ranged between 0.46 and 0.016 for CL and 371 
between 0.92 and 0.03 for VL patients. The difference between positive and negative sera 372 
was similar (30 and 28.4 times for VL and CL, respectively. These findings show that, 373 
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whilst the target protein was produced from a kinesin-related gene of L. braziliensis and 374 
performed well with L. braziliensis patients, antibodies from patients with VL (L. 375 
infantum) were also able to recognise Lbk39. The recombinant protein was also 376 
recognised by sera from Chagas patients. These are interesting results, however, they do 377 
not compromise the use of Lbk39 for serodiagnosis of CL as the other clinical features of 378 
infection in VL or Chagas disease are quite different. In fact, given the difficulty in 379 
making a positive diagnosis for CL, it may be an advantage and facilitate the usage of 380 
Lbk39 as a general immunodiagnostic antigen for both VL and CL, since the main issue 381 
is a lack of existing tools for the latter. A greater sampling of patients with cutaneous 382 
leishmaniases coming from different regions of Latin America will be needed to confirm 383 
if this is a useful approach. The cross-reactivity between the CL and VL patients likely 384 
arises from two factors, the first of which is the conservation between Lbk39 and the 385 
homologue from L. infantum (Suppl. Fig 1), which, while only 59% at the amino-acid 386 
level, is concentrated in several immunogenic repeat motifs. The second factor is the very 387 
high antibody response stimulated by VL infection compared to CL, which also explains 388 
the relatively high values seen in the ELISA results for VL sera with Lbk39, and the high 389 
sensitivity. 390 
The sensitivity and specificity of a leishmaniasis immunodiagnostic test is 391 
influenced by various factors such as antigenic and structural properties of the antigen 392 
itself, the duration of the infection, number of lesions, and variation in the parasite and 393 
host population. Regarding properties of the antigen, although no previous studies have 394 
investigated the levels of antibodies against L. braziliensis kinesin-related proteins in CL 395 
and VL patients until this study, a few have investigated the reaction of antibodies from 396 
CL patients against L. infantum kinesin-related recombinant proteins. For example, 397 
Molinet et al. (2013) found that all of 272 serum samples from patients with CL in Brazil 398 
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were negative when using one commercially available rK39 rapid test. Hartzell et al. 399 
(2008) observed that both the rK39 rapid test and ELISA using the rK39 antigen 400 
demonstrated a positivity of only 10.2 and 28.8%, respectively, in United States soldiers 401 
stationed in Afghanistan and Iraq who had contracted CL (mostly due to L. major). 402 
Likewise, Oliveira et al. (2011) evaluated several recombinant antigens that demonstrated 403 
the ability to identify Leishmania infantum-infected patients and found that CL patients 404 
were generally less well identified. Interestingly, only 3 out of 26 CL patients showed a 405 
positive result using an antigen that encoded a C-terminal fragment of an L. infantum 406 
kinesin. One potentially important difference to the current study is that the recombinant 407 
antigens described by Oliveira et al. were expressed in E. coli, perhaps compromising 408 
their sensitivity for CL diagnosis. According to Moreno et al. (2009), the high titres of 409 
the anti-rK39 antibody in patients with acute VL are explained by expression in the high 410 
number of amastigotes present, compared to asymptomatic patients that have lower 411 
numbers of amastigotes. However, here we show that Lbk39 is capable of detecting 412 
antibodies in CL patients, which also have low numbers of amastigotes. Another factor 413 
to consider is the potential diversity of the diagnostic antigen. In that regard, 414 
Bhattacharyya et al. (2013) showed that there is diversity in rK39 sequences between L. 415 
infantum and L. donovani, which may explain the poorer performance of rK39 in 416 
diagnosis of East African VL due to L. donovani. Therefore, potential diversity in Lbk39 417 
should also be investigated in further studies (Cupolillo et al., 2003). Finally, the reasons 418 
why kinesin-related cytoskeletal proteins have been found to be good antigens for 419 
serodiagnosis is not fully understood but presumably is related to their structure, as they 420 
contain repetitive amino acid sequences thus presumably providing multiple stimulation 421 
of antibody responses.  422 
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Regarding other factors that affect sensitivity and specificity in the current 423 
context, duration of the infection is significant. In patients with recent lesions (1 to 6 424 
months of progression), serological negativity is higher, and parasitological tests are more 425 
sensitive and specific (Costa et al., 1996). Also, in the case of positive serology, the mean 426 
titres are significantly higher in patients with multiple lesions, reflecting the higher 427 
antigenicity induced by a larger number of parasites. Even within the same species, 428 
genetic variability of responses can be high and the antigen used for serological testing 429 
can give different results. For example, the rK39 antigen used to detect VL antibodies in 430 
several regions of the world, shows variable sensitivity and specificity according to 431 
geographical region and ethnic groups (Singh et al., 2009; Mohapatra et al., 2010). 432 
Different host immune responses may also be responsible for the variability of serological 433 
test results. Goto et al. (2009) analysed antibody responses to the rK39 antigen in humans 434 
and dogs with VL, and they noticed that humans showed much stronger immune 435 
responses to the rK39 antigen than dogs, concluding that the rK39 recombinant antigen 436 
is very specific towards detecting VL in humans only. However, Porrozzi et al. (2007) 437 
revealed that the IgG response to the rK39 antigen was variable in asymptomatic dogs 438 
(sensitivity of 66%) and significantly higher in symptomatic dogs (sensitivity of 100%). 439 
Likewise, 33% of L. braziliensis-infected dogs were positive for the rK39, and 11% of 440 
dogs with leptospirosis were also positive showing cross reactivity. For intervention 441 
programmes of leishmaniases in humans and dogs, an ideal serodiagnostic tests must be 442 
able to identify infected and non-infected reservoirs, specifically in dogs (Quinnell et al., 443 
2013), thus providing the possibility of guided control and treatment. 444 
In summary, this study showed that the recombinant Lbk39 protein produced was 445 
able to recognize Leishmania infection in the serum of humans with cutaneous or visceral 446 
leishmaniases in Brazil. This is a particularly important result for the L. braziliensis CL 447 
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patients, where there is a lack of serological tests. Further work is required to investigate 448 
the potential use of this antigen in different population sera, as well as in different 449 
geographical regions in order to determine the specific ability to detect anti-Leishmania 450 
antibody levels in patients with CL or VL. In addition, analysis of the response to Lbk39 451 
by sera of dogs infected with L. infantum should be considered in order to determine how 452 
the antigen behaves in different hosts. 453 
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Figure captions 598 
 599 
Figure 1. A. Linearization and partial digestion of the Lbk39 plasmid with the SwaI 600 
(SmiI) enzyme. MM: molecular mass markers (1kb DNA ladder); Lane 1 (a): 2.9 kbp 601 
fragment related to the E coli part; Lane 1 (b): a larger fragment (approximately 5 kbp) 602 
related to the Lbk39 plasmid; Lane 1 (c): the entire Lbk39 plasmid, linearised, with 603 
8486bp. B. PCR for confirmation of the Lbk39 genomic integration into the chromosomal 604 
18SrRNA (ssu) locus of L tarentolae resulted in two DNA fragments of different sizes: 605 
2.3 kbp fragment size for F2999/F3002 pair of primers (lane 1) and 1.1 kbp fragment size 606 
for F3001/A1715 pairs of primers (lane 2) MW: molecular weight markers.  607 
 608 
Figure 2. The purified Lbk39 recombinant protein expression confirmed by SDS-PAGE. 609 
Lane 1: molecular mass markers (10-225 kDa); Lane 2: crude extract of L. tarentolae 610 
non-transfected; Lane 3: purified Lbk39 recombinant protein; Lane 4: crude extract of L. 611 
tarentolae transfected. 612 
 613 
Figure 3. Receiver operating characteristic (ROC) curve analysis for Lbk39 antigen 614 
compared to the positive control L. braziliensis crude extract of Leishmania (Viannia) 615 
braziliensis (strain MHOM/BR/84/LTB300). A to C = Lbk39 antigen ROC 616 
curve comparing results of the group healthy non-endemic individuals vs. the group with 617 
active skin lesions (A); visceral leishmaniasis (B) and Chagas disease (C). D to F = ROC 618 
curve results from crude extract of the L. (V.) braziliensis in healthy non-endemic 619 
individuals vs. group with active skin lesions (D); visceral leishmaniasis (E) and Chagas 620 




Figure 4. Levels of anti-Lbk39 antibodies detected by means of indirect ELISA in 623 
individuals from CL endemic and non-endemic areas in Brazil compared to levels of anti-624 
L braziliensis antibodies detected by the same technique. Group 0: healthy individuals from 625 
non-endemic areas; Group 1: CL patients with active lesion and culture positives; Group 626 
2: VL: positive patients for VL; Group 3: serum from patients with Chagas disease. 627 
ANOVA p values are shown for each antigen, together with pairwise Tukey’s tests for 628 
comparisons between groups for the same antigen. 629 
